The Indian Patent Office rejected Johnson and Johnson's (NYSE: JNJ) application to extend its patent on tuberculosis treatment, bedaquiline, beyond July 2023. The decision paves...
Benzinga - Benzinga takes a look back at a notable market-related moment that occurred on this date. What Happened? On this day in 1997, Walmart Inc (NYSE: WMT), Johnson &...
The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ) (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage...
E ratio. This is particularly interesting since the healthcare behemoth rarely trades at a discount. With the company boasting six decades of consecutive annual dividend increases...
The Third Circuit can rescue a bankruptcy filing from the tort bar.
From a valuation perspective, Johnson & Johnson has fallen into fair value territory, but we do not consider it dramatically undervalued.
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company’s Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Type | Daily | Weekly | Monthly |
|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Buy |
| Summary | Strong Sell | Strong Sell | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 151.80 | 153.40 | 151.40 | -1.60 | -1.04% | 2.60M | London | |||
| 215.00 | 221.00 | 210.00 | -5.00 | -2.27% | 624.35K | London | |||
| 133.90 | 137.74 | 130.06 | -5.88 | -4.21% | 122.87M | London | |||
| 103.05 | 104.30 | 102.30 | -1.70 | -1.62% | 24.54M | London | |||
| 1,030.00 | 1,030.00 | 1,030.00 | 0.00 | 0.00% | 30.79K | London | |||
| 222.50 | 224.50 | 220.00 | -2.50 | -1.11% | 312.84K | London | |||
| 478.50 | 492.00 | 473.00 | -12.00 | -2.45% | 66.67K | London | |||
| 0.1275 | 0.132 | 0.1305 | -0.0085 | -6.25% | 382.90M | London | |||
| 1,100.00 | 1,160.00 | 1,079.00 | -40.00 | -3.51% | 289.75K | London | |||
| 12.25 | 12.70 | 12.00 | +0.25 | +2.08% | 738.23K | London | |||
| 88.58 | 90.78 | 88.16 | -2.22 | -2.44% | 55.26M | London | |||
| 362.50 | 362.50 | 362.50 | -2.50 | -0.69% | 50.84K | London | |||
| 0.12 | 0.13 | 0.13 | 0.00 | 0.00% | 0.00 | Aquis Exchange | |||
| 1,100.00 | 1,110.00 | 1,088.00 | -6.00 | -0.54% | 110.44K | London | |||
| 94.50 | 92.40 | 92.40 | +2.10 | +2.27% | 193.60K | London |